The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings And IPOs

Biotech stocks came under pressure last week despite two FDA approvals coming through. The FDA approved SAGE Therapeutics Inc (NASDAQ:.....»»

It was an event-filled one for biotech stocks, with the release of a slew of earnings, presentations of clinical trial results an.....»»

The earnings season hasn't panned out well for pharma companies, with Amgen, Inc. (NASDAQ: AMGN), Novartis AG (NYS.....»»

The earnings season hasn't panned out well for pharma companies, with Amgen, Inc. (NASDAQ: AMGN), Novartis AG (NYSE: NVS) and Illumina, Inc. read more.....»»

Biotech stocks came under pressure in the week ending Feb. 22 after advancing in the previous week. The recent week was fairly quiet for the space, with a few earnings reports from small-cap stocks and a handful of conference presentations. read more.....»»

Biotech stocks staged a recovery this week after being in the red in the previous two weeks. AbbVie Inc (NYSE: ABBV)'s psoriasis drug Skyrizi received FDA nod. The week also saw the release of strong quarterly earnings by big European pharma gian.....»»

Biotech stocks are on track to extend their losses, bucking the positive broader market sentiment. The week saw Achaogen Inc (NASDAQ: AKAO) filing for Chapter 11 bankruptcy and negative clinical readouts .....»»

Biotech stocks witnessed a slowdown in momentum last week, which was a relatively slow one in terms of news flow. Amgen, Inc. read more.....»»

Last week was an event-filled one for the biotech space, with M&A, FDA decisions, clinical trial results and earnings all on offer. read more.....»»

Last week was an event-filled one for the biotech space, with M&A, FDA decisions, clinical trial results and&nb.....»»

The ASCO conference closed Tuesday, although presentations at the conference triggered some huge stocks moves. read more.....»»

A bit of a lull took place in the biotech space ahead of earnings season; IPO activity was non-existent, but there was some action on account of clinical trial results. Here's a look at the upcoming week's catalytic events. read more.....»»

A bit of a lull took place in the biotech space ahead of earnings season; IPO activity was non-existent, but there was some action on account of clinical trial results. He.....»»

The upcoming week could see some action due to the presence of a host of catalytic events that include PDUFA dates and earnings releases. Here are are the ones a biotech investor should keep a tab on. Conferences Alzheimer's Association In.....»»

The upcoming week could see some action due to the presence of a host of catalytic events that include PDUFA dates and earnings releases. Here are are the ones a biotech investor should keep a tab on. read more.....»»

Biotech stocks saw modest gains this week, with earnings providing a boost even as clinical trial results elicited a mixed reaction. Eli Lilly And Co (NYSE: LLY), Vertex Pharmaceuticals Incorporated (NA.....»»

Biotech stocks saw modest gains this week, with earnings providing a boost even as clinical trial results elicited a mixed reaction. read more.....»»

The biotech .....»»

The biotech sector notched strong gains last week, capitalizing on the positive overall mark.....»»

After recording stellar gains of 4.3 percent in the week ended Aug. 31 to close the month .....»»